



## **Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**

April 7, 2020

BOSTON--(BUSINESS WIRE)--Apr. 7, 2020-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 127,500 shares of its common stock to nine new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to \$2.48 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on April 1, 2020. The stock options that were granted to the nine new employees will vest at a rate of twenty-five percent (25%) on the one year anniversary of the employee's date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employees continue to serve as employees of or other service providers to Verastem Oncology on each such vesting date.

### **About Verastem Oncology**

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it's personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin's lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit [www.verastem.com](http://www.verastem.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200407005633/en/): <https://www.businesswire.com/news/home/20200407005633/en/>

#### *Investors:*

John Doyle  
Vice President, Investor Relations & Finance  
+1 781-292-4279  
[jdoyle@verastem.com](mailto:jdoyle@verastem.com)

#### *Media:*

Lisa Buffington  
Corporate Communications  
+1 781-292-4205  
[lbuffington@verastem.com](mailto:lbuffington@verastem.com)

Source: Verastem Oncology